Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adrian Sacher

Showing results (31-40 of 56) with videos related to

Pageof 6
Sort By:
Lung Cancer (Amsterdam, Netherlands)|February 20, 2022
Treatment patterns and outcomes in early-stage ALK-rearranged non-small cell lung cancerSabine Schmid, Miguel Garcia, Sierra Cheng, et al.
JTO Clinical and Research Reports|April 17, 2025
Myasthenia Gravis in Patients Treated With Immune Checkpoint InhibitorsAbdulrahman Alghabban, Lucy Corke, Hans Katzberg, et al.
Clinical Lung Cancer|June 2, 2024
Immediate Versus Deferred Systemic Therapy in Patients With MesotheliomaSabine Schmid, Luna Zhan, Miguel Garcia, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 25, 2011
Treatment of the elderly when cure is the goal: the influence of age on treatment selection and efficacy for stage III non-small cell lung cancerLinda E Coate, Christine Massey, Andrew Hope, et al.
Clinical Lung Cancer|February 25, 2023
A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non-Small Cell Lung CancerWade T Iams, Meridith L Balbach, Sharon Phillips, et al.
Lung Cancer (Amsterdam, Netherlands)|June 11, 2020
BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancerRuoshi Shi, Sebastiao N Martins Filho, Ming Li, et al.
Clinical and Translational Radiation Oncology|February 3, 2025
Real-world outcomes of prophylactic cranial irradiation utilization and efficacy for patients with extensive-stage small cell lung cancer treated with consolidative thoracic radiotherapyAbdul H Lone, Rohan Salunkhe, Vijithan Sugumar, et al.
Nature Medicine|October 9, 2023
ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial resultsValsamo Anagnostou, Cheryl Ho, Garth Nicholas, et al.
Cancer Medicine|October 26, 2019
Real-world health utility scores and toxicities to tyrosine kinase inhibitors in epidermal growth factor receptor mutated advanced non-small cell lung cancerShirley Xue Jiang, Ryan N Walton, Katrina Hueniken, et al.
Therapeutic Advances in Medical Oncology|December 30, 2024
Analysis of outcomes in resected early-stage NSCLC with rare targetable driver mutationsNadia Ghazali, Jamie Feng, Katrina Hueniken, et al.
Pageof 6

Showing results (31-40 of 56) with videos related to

Sort By:
Pageof 6
Lung Cancer (Amsterdam, Netherlands)|February 20, 2022
Treatment patterns and outcomes in early-stage ALK-rearranged non-small cell lung cancerSabine Schmid, Miguel Garcia, Sierra Cheng, et al.
JTO Clinical and Research Reports|April 17, 2025
Myasthenia Gravis in Patients Treated With Immune Checkpoint InhibitorsAbdulrahman Alghabban, Lucy Corke, Hans Katzberg, et al.
Clinical Lung Cancer|June 2, 2024
Immediate Versus Deferred Systemic Therapy in Patients With MesotheliomaSabine Schmid, Luna Zhan, Miguel Garcia, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 25, 2011
Treatment of the elderly when cure is the goal: the influence of age on treatment selection and efficacy for stage III non-small cell lung cancerLinda E Coate, Christine Massey, Andrew Hope, et al.
Clinical Lung Cancer|February 25, 2023
A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non-Small Cell Lung CancerWade T Iams, Meridith L Balbach, Sharon Phillips, et al.
Lung Cancer (Amsterdam, Netherlands)|June 11, 2020
BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancerRuoshi Shi, Sebastiao N Martins Filho, Ming Li, et al.
Clinical and Translational Radiation Oncology|February 3, 2025
Real-world outcomes of prophylactic cranial irradiation utilization and efficacy for patients with extensive-stage small cell lung cancer treated with consolidative thoracic radiotherapyAbdul H Lone, Rohan Salunkhe, Vijithan Sugumar, et al.
Nature Medicine|October 9, 2023
ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial resultsValsamo Anagnostou, Cheryl Ho, Garth Nicholas, et al.
Cancer Medicine|October 26, 2019
Real-world health utility scores and toxicities to tyrosine kinase inhibitors in epidermal growth factor receptor mutated advanced non-small cell lung cancerShirley Xue Jiang, Ryan N Walton, Katrina Hueniken, et al.
Therapeutic Advances in Medical Oncology|December 30, 2024
Analysis of outcomes in resected early-stage NSCLC with rare targetable driver mutationsNadia Ghazali, Jamie Feng, Katrina Hueniken, et al.
Pageof 6